NEW TOPICAL FORMULATION THAT MODULATES NOCIPIRATION SIGNAL PATHWAYS

Description

technical field

[0001] The invention relates to a novel cosmetic or dermatological composition for topical application, in the form of a dispersion comprising a combination of carbomer, a natural polysaccharide, and a hydrophobically modified copolymer. This composition has the ability to modulate nociceptive pathways and is also useful in the protection and / or treatment of skin experiencing discomfort and / or irritation, or skin affected by inflammatory dermatosis. Previous technique

[0002] The epidermis is a stratified epithelium that acts as a protective barrier against its environment and external aggressions. Among its many physiological functions, the epidermis provides a biological, physical, and chemical barrier against the invasion of the body by microorganisms. This physical barrier property of the epidermis is primarily linked to its structure. The epidermis is conventionally divided into a basal layer of keratinocytes, constituting the germinal layer of the epidermis; a spinous layer composed of several layers of polyhedral cells; and finally, a set of upper layers called the stratum corneum, composed of keratinocytes at the final stage of their differentiation, known as corneocytes.A dysfunction in the structural organization of epidermal cells, or a defect in the chemical barrier function of the epidermis, can result in a cutaneous inflammatory state.

[0003] The skin is an organ with a very dense innervation that extends to the most superficial layers, with the exception of the stratum corneum. The epidermis is also characterized by numerous free nerve endings reaching its outermost layers. These nerve endings originate from sensory neurons in the spinal ganglia located along the spinal cord. These neurons therefore possess extremely long axons that transmit sensory information—touch, heat, and even pain—from the skin to the brain. The density of innervation varies depending on the area of ​​the body. Thus, in humans, the hands and face are richly innervated compared to the back or abdomen.

[0004] The skin contains sensory and autonomic nerve fibers, both belonging to the peripheral nervous system. Sensory nerve endings respond to a variety of physiological stimuli such as heat, cold, touch, mechanical stretching, and UV radiation. Some fibers can even be activated by a variety of chemical substances or by biological factors such as microbiological agents or plant proteases.

[0005] Everyone has experienced pain. Pain is not an illness, but a warning. Pain that is familiar and short-lived is considered normal. Indeed, pain is an alarm signal that informs the body. It is defined by the IASP (International Association for the Study of Pain) as "an unpleasant sensory and emotional experience associated with actual or potential tissue damage, or described in terms of such damage." This definition clearly explains that everyone experiences pain differently. This can range from acute pain, such as that from a needle or a cut, to chronic pain due to a persistent problem, such as arthritis. All parts of the body can experience pain, including acute pain; the skin is no exception.Pain in the skin can manifest in various ways: burning, stinging, electric shocks, tingling, itching, etc. Furthermore, some unexplained, more recurrent skin pain may be due to neuropathies, specifically small fiber neuropathies. These can cause unexplained pain manifesting as tingling or pulling sensations even when the skin appears normal: this is known as allodynia.

[0006] Allodynia is pain triggered by a stimulus that is normally painless. For example, a light touch of the skin or a slight sensation of heat or cold can then be painful.

[0007] Neurons that respond selectively to stimuli generated by tissue damage are called nociceptors. They consist of Aδ and C fibers. Aδ fibers are primarily mechano-nociceptors involved in acute, well-localized pain. C fibers, on the other hand, are polymodal nociceptors involved in dull, poorly localized pain.

[0008] Between the peripheral pain message and the perception of pain, there is an electrical and chemical cascade that is divided into four distinct stages: Transduction is the encoding of the sensory message for the transmission of nociceptive information to the dorsal horn of the spinal cord. Transduction is carried out by receptor-gated channels that depolarize the free terminal of nociceptors, thereby activating voltage-gated sodium channels (NaV1.6-1.9) that allow the generation and propagation of action potentials. At the central terminal of the nociceptor in the dorsal horn of the spinal cord, action potentials trigger the influx of calcium, which allows the release of numerous neuromodulators and signaling molecules into the synaptic cleft. At this level, there is modulation of the nociceptive signal, either excitatory or inhibitory; during transmission, the nociceptive action potential travels through the nociceptor to the dorsal horn of the spinal cord, where it is transmitted to a spinothalamic second-order neuron.The secondary neuron immediately crosses into the spinal cord, passing under the ependymal canal to form the spinothalamic tract in a ventrolateral position within the spinal cord. It then carries the information to various regions of the ventrobasal and centromedian complexes of the somatosensory thalamus, where it makes synaptic contact with the third neuron. Modulation encompasses all the mechanisms by which the nerve impulse from nociceptors can be modulated at both the spinal and central levels. In particular, there are descending inhibitory controls originating in the brainstem that act on the spinal transmission of nociceptive messages.Following peripheral nociceptive stimulation, diffuse nociceptive inhibitory control is activated from numerous brainstem regions, involving noradrenergic, serotonergic, and enkephalinergic pathways. Pain perception is effective when nociceptive information reaches the brain via thalamocortical pathways. The third neuron, or thalamocortical neuron, then conducts nociceptive information to various regions of the somatosensory cortex and certain limbic structures. Higher pain centers enable the complex balance between the sensory / discriminative and affective / emotional components of pain. Activation of the prefrontal cortex may be related to the cognitive aspects of pain perception.

[0009] Skin pain is relatively common, affecting approximately one in three people. It's important to note that 60% of patients who complain of skin pain have a dermatosis. Furthermore, about 50% of patients with a dermatosis report experiencing skin pain, while only 10-15% of patients without a dermatosis report skin pain. The main painful dermatoses appear to be atopic dermatitis, eczema and psoriasis, rosacea, and reactive skin, meaning fragile, intolerant skin. The characteristics of the pain experienced by patients are primarily itching, burning, and tingling.

[0010] Millions of people are affected by these skin pains; in France, nearly 4 million people complain of skin pain and suffer from atopic dermatitis, psoriasis, or contact eczema.

[0011] Inflammatory dermatoses are skin and mucous membrane conditions, often painful, characterized by unsightly manifestations such as redness and scaling patches. Several conditions are grouped under the term inflammatory dermatoses. Examples include, but are not limited to: atopic dermatitis, eczema, psoriasis, rosacea, lichen planus, prurigo, seborrheic dermatitis, and acne. These dermatoses often result from inflammatory processes and immune disorders.

[0012] Atopic dermatitis is the cutaneous manifestation of atopy. It is a chronic inflammatory skin condition occurring in individuals with a genetic predisposition. It affects 15 to 30% of children and 2 to 10% of adults. Its prevalence is steadily increasing in industrialized countries; it has doubled or even tripled in the last three decades and is now considered a major public health concern. Atopic dermatitis is often associated with other atopic disorders, such as allergic rhinitis and asthma; this is known as the atopic march. This condition most often appears during early childhood and is characterized by repeated eruptions over several years. It progresses in flare-ups interspersed with spontaneous remissions. The lesions are characterized by significant skin dryness associated with inflammatory manifestations: erythematous papular, vesicular, scaly, and intensely itchy eruptions.Histologically, atopic dermatitis, like many dermatoses, is characterized by an infiltration of lymphocytes, monocytes, and eosinophils around small blood vessels and capillaries. Biochemically, it is characterized by the expression of cytokines such as thymic stromal lymphopoietin (TSLP), a major protein in triggering the inflammation associated with atopic dermatitis. Furthermore, chemokines, particularly interleukin-8 (IL-8), and lipid mediators of inflammation such as prostaglandin 6KF1α have been shown to be strongly implicated in dermatoses such as atopic dermatitis and in chronic inflammatory diseases in general.

[0013] Eczema is an itchy skin condition characterized by inflammation accompanied by redness, small blisters, scaling, and itching. It can begin very early in life and is even observed in infants. Affected individuals experience periods commonly referred to as "eczema flare-ups," during which symptoms worsen. These flare-ups, which vary in duration, are interspersed with periods of remission. Eczema is believed to have a genetic component, but environmental factors such as the presence of chemical irritants or stress can influence its development.

[0014] Psoriasis, a quintessential inflammatory skin disease, is characterized by the appearance of thick, scaly plaques of skin. These plaques are present on various parts of the body, most often on the elbows, knees, and scalp. This chronic condition progresses in cycles, with periods of remission. Psoriasis can be very unpleasant and even painful when it appears on the palms of the hands, the soles of the feet, or in skin folds. There are several types of psoriasis, the most common form being plaque psoriasis, also known as psoriasis vulgaris. Other forms include guttate, erythrodermic, and pustular psoriasis.

[0015] Rosacea is a common, chronic, and progressive inflammatory skin condition linked to vascular relaxation. It affects the small blood vessels of the face. It frequently affects people with fair skin and can have significant psychological and emotional consequences. The name of this condition refers to the characteristic discoloration that the face takes on during the course of the disease.

[0016] Lichen planus is an itchy skin rash affecting only adults. It is an inflammatory skin condition of unknown origin. This dermatosis affects the skin, mucous membranes, as well as the hair and nails.

[0017] Prurigo is an intense itching of the skin with erythematous and vesicular papules and scratch marks. It is most often caused by an exaggerated sensitivity to insect bites, a sensitivity that lasts an abnormally long time and is particularly common in young children.

[0018] Seborrheic dermatitis is a chronic inflammatory skin condition that affects areas rich in sebaceous glands, namely the scalp and face. It is caused by a yeast, Malassezia, present in the skin and which thrives in sebum. This condition progresses in flare-ups, which are exacerbated by stress, lack of sun exposure, and pollution.

[0019] Acne is a common skin condition resulting from inflammation of the pilosebaceous follicles, largely due to colonization by Cutibacterium acnes in the infundibulum.

[0020] Inflammation is a normal immune response of the body to an attack such as infection, heat, mechanical stress, chemical injury, or an allergic reaction. It is characterized by four elements: redness, heat, swelling, and pain.

[0021] Acute skin inflammation is an immediate response to an irritant, of short duration (a few days or weeks), often with a sudden onset, and characterized by intense swelling. Acute inflammations heal spontaneously or with treatment. Chronic inflammation occurs when the inflammation does not heal spontaneously, persists, or worsens for several months or even years. The inflammatory reaction is a dynamic process involving several successive stages: vascular (vasodilation), leukocyte diapedesis, immune cell chemotaxis, and finally, debridement. Leukocyte diapedesis corresponds to the active crossing of vascular walls by leukocytes and the accumulation of circulating immune cells—lymphocytes, neutrophils, and monocytes—at the site of injury.Neutrophils attract other inflammatory cells by chemotaxis and clear the injured site by secreting antimicrobial substances and proteases. Monocytes migrate by chemotaxis and differentiate into macrophages, which clear the injured area. They secrete growth factors, inflammatory cytokines such as IL-1 (particularly IL-1β), TNFα, proteases, prostaglandins, and IFNs, which maintain and / or amplify inflammation. Debridement follows the vascular phase and occurs concurrently with leukocyte diapedesis. It involves the elimination of necrotic tissue and pathogens.

[0022] Cutaneous neurogenic inflammation is defined as the induction and / or amplification of a primary inflammatory process by nerve endings. It is thus a skin inflammation induced by the activation of intraepidermal nerve fibers that secrete neuropeptides such as substance P. Cutaneous neurogenic inflammation is particularly implicated in irritated skin, skin experiencing discomfort, and even skin affected by inflammatory dermatoses, especially pruritic ones. Pruritus is defined as an unpleasant sensation that causes the urge to scratch. The concept of pruriceptors, particularly specific ones that allow the perception of pruritus, has recently emerged, but their distinction from the family of nociceptive receptors remains debated. These pruriceptors utilize intraepidermal fibers of type Aδ and especially type C.They secrete neuropeptides: substance P, calcitonin gene-related peptide (CGRP), and vasoactive intestinal peptide (VIP). Recently, the role of proteases (trypsin, cathepsin G, thrombin, etc.) in the induction of pruritus has been clearly established. Indeed, their receptor PAR-2 ​​has been defined as the second major pathway for pruritus activation (Misery et al., Nat. Rev. Neurol. 10, 408-416, 2014).

[0023] Intradermal nerve fibers interact directly or indirectly with skin cells and cells of the endocrine, lymphatic, and immune systems. These interactions have led to the definition of a neuro-immuno-endocrine-cutaneous system. For this system to function, it requires a common language comprised of molecules of different types: neurotransmitters, cytokines, and growth factors. These molecules are synthesized and released by skin cells, resident and recruited immune cells, and intraepidermal nerve endings. Epidermal and dermal cells can also produce neurotransmitters, enzymes, neurotrophins, cytokines, chemokines, and growth factors. These mediators regulate cutaneous innervation and the inflammatory response.In cases of inflammation, immune cells in transit or constitutively present in the skin can be activated by these mediators secreted by sensory nerve endings and skin cells. This process leads to a second wave of cytokine and neurotransmitter release, which generates a feedback loop that amplifies inflammation.

[0024] A new concept has recently emerged, suggesting that keratinocytes are also major players in neurogenic cutaneous inflammation.

[0025] Besides inflammatory dermatoses, skin pain is common in patients with reactive skin, which reacts to stimuli that have no effect on other skin types. This hyper-reactivity of the skin results from a decreased tolerance threshold. The more reactive the skin, the lower the threshold.

[0026] Hyper-reactive skin, or highly reactive skin, is a skin condition that is unpleasant for those affected, but very common and can cause visible skin reactions such as dryness, redness, and peeling. However, it can also cause invisible and therefore subjective reactions, described as sensations of burning, itching, tightness, or tingling, among others.

[0027] Painful skin is defined as skin that experiences unpleasant sensations, such as tingling, itching, or burning, sometimes in reaction to various irritants of varying intensity that would be well tolerated by normal skin. A more extreme and common form of painful skin is hypersensitive skin, characterized by unpleasant sensations of discomfort and visible reactions when it comes into contact with external or internal stimuli that would ordinarily be harmless, such as extreme temperatures, chemicals, or UV radiation. These sensations and their intensity vary from person to person, making diagnosis all the more difficult.

[0028] Three signs are commonly observed in people with painful skin: an altered skin barrier, highly reactive sensory fibers in the epidermis, and redness.

[0029] The impaired skin barrier also causes trans-epidermal dehydration, which makes the skin more susceptible to the penetration of irritating external factors.

[0030] Hyper-reactive or overstimulated sensory fibers in the epidermis react faster and more intensely than those in normal skin. These sensory fibers trigger unpleasant skin sensations described as, among others, tingling, burning, or tightness of the skin on the face or scalp, without any visible signs. In the most severe cases, these invisible signs are accompanied by dry skin, rashes, or redness.

[0031] In the absence of unpleasant skin sensations, the skin is not considered hypersensitive. However, redness itself is not specific to hypersensitive skin.

[0032] Reactions in hypersensitive skin can be triggered by environmental, psychological, external, and / or mechanical factors, including but not limited to the following. Environmental factors include sudden temperature changes, heat, cold, wind, sun, and air pollution. Psychological factors include strong emotions and stress. External factors include exposure to certain cleaning products, spicy food, alcohol, perfumes, detergents, swimming pools, excessively hard water, baths, and showers. Mechanical factors involve pressure on the skin.

[0033] Preventing or treating skin pain involves several solutions. There are dermal compositions containing local anesthetics such as butoform, ethoform, or other products with equivalent functions. However, topical anesthetics often have the drawback of causing systemic sensitization rather than just local sensitization as desired. Furthermore, they frequently cause allergic reactions ranging in severity from simple dermatitis to anaphylactic shock.

[0034] Furthermore, analgesics are medications designed to reduce pain. There are three levels defined according to their activity. Level 1 includes paracetamol and non-steroidal anti-inflammatory drugs (NSAIDs), such as aspirin, ibuprofen, and noramidopyrine, which are prescribed first for mild to moderate pain. They act primarily by inhibiting cyclooxygenase. Level 2 includes weak opioid analgesics such as codeine, dihydrocodeine, and tramadol. These substances act on specific receptors in the brain responsible for pain relief. Level 3 includes strong opioid analgesics such as morphine and its derivatives. They are used for severe pain or pain that is resistant to level 2 analgesics. All of these analgesics have side effects, ranging from gastric problems to addiction.

[0035] Alongside all these medications, there are gentler solutions; we can mention certain plants and homeopathic remedies, such as arnica, which has demonstrated its anti-inflammatory and analgesic properties, especially if administered within minutes of the shock.

[0036] There are also sprays without therapeutic molecules that provide instant cold to numb the pain. The cold causes blood vessels to constrict and prevents blood flow. Through mechanoreceptors and / or TRPM8 activation, the cold stimulates interneurons to modulate nociceptive pathways as a counter-stimulus at the level of the dorsal horn of the spinal cord. These sprays may contain gases commonly used in cryotherapy, such as butane, isobutane, propylene glycol, and methylal. They have the disadvantage of containing propellant gases, which are flammable and subject to criticism.

[0037] US 2004 / 076696 A1 describes a composition based on witch hazel and peppermint with a cooling effect intended to relieve burns, itching and stinging caused by tweezing and shaving, itchy skin and scalp, headaches, fatigue, sunburn, hives and insect bites.

[0038] EP 3 269 354 A1 describes water-based cosmetic compositions comprising agar, xanthan gum and a hydrophilic polymer and providing a feeling of freshness upon use.

[0039] The article "Topical acetylsalicylic, salicylic acid and indomethacin suppress pain from experimental tissue acidosis in human skin" by Kay H. Steen et al (Pain, 62 (1995) 339-347) describes a study in which acetylsalicylic acid, salicylic acid and indomethacin were applied topically and tested in an experimental model of pain providing direct excitation of nociceptors through skin tissue acidosis.

[0040] US 2010 / 256100 describes a roll-on applicator containing a composition including a high level of salicylic acid intended in particular for the care of oily and / or acne-prone and / or seborrheic skin.

[0041] There is a real need for new cosmetic or dermatological compositions for soothing topical use, but also useful for modulating nociceptive pathways, for preventing and / or treating neurogenic skin inflammation, for relieving all skin pain, while avoiding side effects, particularly those of local anesthetics, analgesics, painkillers and gases providing instant cold. Detailed description of the invention

[0042] The present invention aims to address these needs. Indeed, the inventors have unexpectedly discovered that the combination of three gelling agents offers characteristics of interest for soothing topical use. This combination is also useful for modulating nociceptive pathways, preventing and / or treating neurogenic skin inflammation, relieving skin pain, and more specifically, skin pain associated with inflammatory dermatoses. These effects are achieved, in particular, by providing a cooling sensation upon application of a composition containing this combination of three gelling agents; this cooling effect helps reduce edema formation and vasoconstriction of blood vessels, thereby limiting inflammation and producing an analgesic effect.

[0043] A first object of the invention relates to a cosmetic or dermatological composition comprising an association of carbomer, natural polysaccharide, and hydrophobically modified copolymer; these three compounds can be defined in the remainder of this text by the generic term "gelling agents".

[0044] The cosmetic or dermatological composition is presented as an emulsion comprising an oily phase and an aqueous phase. The aqueous phase includes a combination of carbomer, natural polysaccharide, and hydrophobically modified copolymer.

[0045] Thus, the present invention relates to a cosmetic or dermatological composition in the form of an emulsion for topical application, comprising: an oily phase; and an aqueous phase comprising a carbomer, a natural polysaccharide and a hydrophobically modified crosslinked acrylic or methacrylic copolymer; the composition comprising 0.10 to 0.25%, preferably 0.05 to 0.20%, by weight of carbomer relative to the total weight of the composition.

[0046] Unless explicitly stated otherwise, the term "a" refers to one or more.

[0047] Thus, the aqueous phase comprises one or more carbomers, one or more natural polysaccharides and one or more hydrophobically modified crosslinked acrylic or methacrylic copolymers.

[0048] In other words, the present invention relates to a cosmetic composition comprising a dispersion of a non-gelled oily phase in a gelled aqueous phase, said aqueous phase comprising at least the association of carbomer, natural polysaccharide, and hydrophobically modified copolymer.

[0049] Gelling agents are macromolecules of natural or synthetic origin capable of forming gels by trapping a large amount of solvent, usually water, in a three-dimensional network.

[0050] The first gelling agent is a carbomer. Carbomers are hydrophilic synthetic polymers of acrylic acid, crosslinked with pentaerythritol allylic ethers or sucrose allylic ethers. Carbomers are used as stabilizing emulsifiers or as thickening agents with the appearance of an aqueous gel. An example is the commercial product Carbopol®. Its CAS number is 9007-16-3.

[0051] The second gelling agent is a natural polysaccharide. Natural polysaccharides consist of linear or branched chains of saccharide units linked by glycosidic bonds. These polysaccharides are produced by a wide variety of species, including plants, animals, bacteria, and fungi. The natural polysaccharide may be chosen, without limitation, from scleroglucan gum, xanthan gum, guar gum, pectins, carrageenans, alginates, gum arabic, tragacanth gum, starches, and agar. Preferably, the natural polysaccharide is scleroglucan gum. This can be obtained by the fermentative action of filamentous fungi. Sclerotium rolfsiion a glucose substrate. The mixture is purified with alcohol (ethanol or isopropanol), pressed, dried, and ground. The resulting powder can optionally be sterilized by irradiation or high pressure. Scleroglucan gum is a homopolysaccharide with a very high molecular weight, the hydrolysis of which yields only glucose molecules. The main chain consists of β-D glucose molecules linked in a β(1-3) fashion. Every third glucose molecule has a β-D glucose molecule linked in a β(1-6) fashion, preventing chain aggregation. Scleroglucan gum is also called sclerotium gum. It is commercially available and is marketed in particular under the name ACTIGUM ®< CS by the company SANOFI BIO INDUSTRIES, and in particular ACTIGUM ®< CS 11, and under the name AMIGEL ®< , AMIGUM and AMIGEL ®< GRANULE by the company ALBAN MULLER INTERNATIONAL, or under the name Tinoderm ®< SG-L by the BASF group.This scleroglucan gum can optionally be modified, particularly by enzyme treatments or by using modified strains. However, in a preferred embodiment, the scleroglucan gum is not modified.

[0052] The third gelling agent is a hydrophobically modified, crosslinked acrylic or methacrylic copolymer. This typically involves a copolymer of acrylic or methacrylic acid and a long alkyl acrylate chain crosslinked with, for example, an allyl ether of pentaerythritol or sucrose. The alkyl chain advantageously comprises at least 10 carbon atoms, and more advantageously, 10 to 30 carbon atoms. Pemulen®< TR-2 is an example. The Pemulen®< TR-1 and TR-2 polymers possess numerous hydrophilic groups within their structure, providing gelling properties, and alkyl groups with an affinity for the oil phase, responsible for their emulsifying functions. This dual affinity allows the formation of emulsified microgels for lotions and creams. The gel phase is adsorbed around each oil droplet, providing stabilization through physical repulsion.

[0053] The composition according to the invention comprises carbomer in a content of between 0.10 and 0.25%, in particular between 0.15 and 0.20% by weight relative to the total weight of the composition. It is understood that if the composition comprises several carbomers, the total carbomer content is between 0.10 and 0.25%, in particular between 0.15 and 0.20% by weight relative to the total weight of the composition.

[0054] The composition according to the invention may comprise the natural polysaccharide in a content of between 0.01 and 0.15%, in particular between 0.05 and 0.10% by weight relative to the total weight of the composition. It is understood that if the composition comprises several natural polysaccharides, the total content of natural polysaccharides is between 0.01 and 0.15%, in particular between 0.05 and 0.10% by weight relative to the total weight of the composition.

[0055] The composition according to the invention may comprise the hydrophobically modified copolymer in a content of between 0.10 and 0.25%, in particular between 0.12 and 0.20% by weight relative to the total weight of the composition. It is understood that if the composition comprises several hydrophobically modified copolymers, the total content of hydrophobically modified copolymers is between 0.10 and 0.25%, in particular between 0.12 and 0.20% by weight relative to the total weight of the composition.

[0056] In a particular embodiment, when the quantities of carbomer, natural polysaccharide, and hydrophobically modified copolymer in the ternary association according to the invention are expressed in parts, this association comprises between 1 and 5 parts of carbomer(s), between 0.5 and 3 parts of natural polysaccharide(s), and between 1 and 5 parts of hydrophobically modified copolymer(s). Preferably, the association according to the invention comprises, in parts, 1 to 3 parts of carbomer(s), 0.5 to 2 parts of natural polysaccharide(s), and 1 to 3 parts of hydrophobically modified copolymer(s). Even more preferably, the association according to the invention comprises, in parts, 2 parts of carbomer(s), 1 part of natural polysaccharide(s), and 2 parts of hydrophobically modified copolymer(s).

[0057] Preferably, the ratio of carbomer(s) / natural polysaccharide(s) / hydrophobically modified copolymer(s) is a weight ratio of 2 / 1 / 2 respectively.

[0058] In some embodiments, the aqueous phase comprises a single carbomer, a single natural polysaccharide and a single hydrophobically modified crosslinked acrylic or methacrylic copolymer.

[0059] The aqueous phase of a composition according to the invention comprises water and optionally at least one water-soluble solvent.

[0060] In the present invention, "water-soluble solvent" refers to a compound that is liquid at room temperature and miscible with water. The water-soluble solvents usable in the composition of the invention may also be volatile.

[0061] Among the water-soluble solvents that can be used in the composition according to the invention, we can mention in particular lower monoalcohols having 1 to 5 carbon atoms such as ethanol and isopropanol, polyols, in particular glycols having 2 to 8 carbon atoms such as ethylene glycol, propylene glycol, 1,3-butylene glycol and dipropylene glycol, C3 and C4 ketones and C2-C4 aldehydes.

[0062] According to one embodiment of the invention, the aqueous phase of a composition according to the invention may comprise at least one C2-C32 polyol, preferably C3-C16.

[0063] For the purposes of this invention, "polyol" means any organic molecule comprising at least two free hydroxyl groups.

[0064] Preferably, a polyol according to the present invention is present in liquid form at room temperature.

[0065] A polyol suitable for the invention may be an alkyl-type compound, linear, branched or cyclic, saturated or unsaturated, having on the alkyl chain at least two -OH functions, in particular at least three -OH functions, and more particularly at least four -OH functions.

[0066] Advantageously, the polyol can be selected from ethylene glycol, pentaerythritol, trimethylolpropane, propylene glycol, 1,3 propanediol, butylene glycol, isoprene glycol, pentylene glycol, hexylene glycol, glycerol, polyglycerols, such as glycerol oligomers like diglycerol, polyethylene glycols, and mixtures thereof.

[0067] According to a preferred embodiment of the invention, said polyol is selected from ethylene glycol, propylene glycol, 1,3 propanediol, butylene glycol, glycerol, polyglycerols, polyethylene glycols, and mixtures thereof.

[0068] According to a particular mode, the composition according to the invention may comprise at least propylene glycol.

[0069] According to another particular mode, the composition according to the invention may comprise at least glycerol.

[0070] The aqueous phase, which includes the combination of the three gelling agents, water and possibly at least one water-miscible solvent, may be present in the composition in a content ranging from 5% to 95%, preferably from 30% to 90%, even more preferably from 60% to 90% by weight, even more preferably from 85% to 90% by weight, relative to the total weight of said composition.

[0071] According to the invention, an oily phase is dispersed in a gelled aqueous phase. It includes all liquid fats, generally oils.

[0072] The oil phase is advantageously non-gelled.

[0073] By non-gelled oil phase, we mean that the oil phase does not contain gelling agents and / or thickeners.

[0074] In the context of the invention, the oily phase is typically non-volatile.

[0075] The non-volatile oil phase according to the invention refers to a variety of non-volatile oils suitable for cosmetic or dermatological formulations. The non-volatile oil phase may be composed of a wide variety of synthetic, natural, or organic oils, a non-exhaustive list of which is given for illustrative purposes: esters: examples of non-volatile oil usable according to the invention include esters of formula RCO-OR' with R and R', identical or different, representing a chain, linear or branched, of an alkyl, alkenyl, alkoxycarbonylalkyl, or alkoxycarbonyloxyalkyl having from 1 to 25 carbon atoms, preferably from 4 to 20 carbon atoms. Examples of such esters include isotricedyl isononate, PEG-4 diheptanoate, isostearyl neopentanoate, tridecyl neopentanoate, cetyl octanoate, cetyl palmitate, cetyl ricinoleate, cetyl stearate, cetyl myristate, coco dicaprylate / caprate, decyl isostearate, isodecyl oleate, isodecyl neopentanoate, isohexyl neopentanoate, octyl palmitate, dioctyl malate, tridecyl octanoate, myristyle myristate, octododecanol;glyceride esters of fatty acids: oil may also include fatty acid esters of natural fatty acids, or triglycerides of animal or vegetable origin. Such examples include castor oil, lanolin oil, triisocetyl citrate, triglycerides having 10 to 18 carbon atoms, caprylic / capric triglycerides, coconut oil, corn oil, cottonseed oil, linseed oil, mink oil, olive oil, palm oil, illipe butter, rapeseed oil, soybean oil, sunflower oil, walnut oil and equivalent;fatty acid glycerides: suitable oils also include synthetic or semi-synthetic glyceryl esters, such as mono-, di-, triglycerides of fatty acids, which are modified natural oils or fats, for example, glyceryl stearate, glyceryl dioleate, glyceryl distearate, glyceryl trioctanoate, glyceryl distearate, glyceryl linoleate, glyceryl myristate, glyceryl isostearate, PEG castor oils, PEG glyceryl oleates, PEG glyceryl stearates, and the like; and non-volatile hydrocarbons: also very suitable for the composition according to the invention as a non-volatile oil phase are non-volatile hydrocarbons such as paraffins, isoparaffins, mineral oils, and the like.

[0076] The preferred non-volatile oily phase according to the invention is a fatty acid glyceride ester, in particular a caprylic / capric triglyceride.

[0077] Advantageously, the composition according to the invention comprises between 5 and 95% by weight, preferably between 10 and 70% by weight, even more preferably between 10 and 40% by weight, even more preferably between 10 and 15% by weight of oily phase relative to the total weight of the composition.

[0078] The compositions according to the invention may also include additional cosmetic and dermatological active ingredients. These compositions may include cosmetic adjuvants selected from opacifiers, stabilizers, preservatives, polymers, perfumes, aqueous-phase thickening or gelling agents other than carbomer, sclerotium gum, and Pemulen®, sunscreens, dermatological or cosmetic active ingredients, fillers, suspending agents, colorants, or any other ingredient commonly used in cosmetics for this type of application. It is a matter of routine practice for a person skilled in the art to adjust the nature and quantity of additives present in the compositions according to the invention so that their desired cosmetic properties are not affected.

[0079] As explained above, a composition according to the invention can advantageously be cosmetic or dermatological.

[0080] In this particular embodiment, a composition according to the invention being intended for topical application, it contains a physiologically acceptable medium.

[0081] By "topical application" we mean an application to the skin, mucous membranes and / or hair.

[0082] For the purposes of the present invention, "physiologically acceptable medium" means a medium compatible with the skin, mucous membranes and / or hair.

[0083] Thus, a physiologically acceptable environment is notably one that is cosmetically or dermatologically acceptable.

[0084] In the present invention, "cosmetically or dermatologically acceptable" means something useful in the preparation of a cosmetic or dermatological composition, which is generally safe, non-toxic and neither biologically nor otherwise undesirable, and which is acceptable for cosmetic or dermatological use, in particular by topical application.

[0085] According to a particular embodiment of the invention, the cosmetic or dermatological composition is a thixotropic composition.

[0086] The commonly accepted definition of thixotropy is as follows: a composition is commonly called thixotropic if, starting from a state of rest for a sufficiently long period, its viscosity decreases over time and its structure changes when a constant shear gradient is applied. Reversibly, if the shear is stopped, the viscosity increases again, and the composition gradually recovers the consistency and structure it had at rest. This thixotropic effect is illustrated in Example 3.

[0087] A watery sensation is often associated with a lasting cooling effect provided by the composition. A composition providing a lasting cooling effect is defined as one that, after application, induces a perceptible sensation of reduced skin temperature, this cooling effect lasting from the time of application until at least 5 minutes after application. Indeed, the perceived cooling effect is not measurable; it is a subjective notion. The cooling effect felt upon application of the composition according to the invention is clearly demonstrated in Example 4. For the purposes of this description, the terms cool, cold, and freshness will be used interchangeably.

[0088] The composition according to the invention is particularly intended for the treatment of skin and mucous membranes and may be in the form of ointments, creams, milks, salves, powders, soaked swabs, solutions, gels, sprays, foams, suspensions, lotions, sticks, and shampoos. It may also be in the form of suspensions of microspheres or nanospheres or lipid or polymeric vesicles, or polymeric patches and hydrogels allowing controlled release. This topical composition may be in anhydrous form, aqueous form, or emulsion form.

[0089] The composition according to the invention is preferably administered in the form of a sprayable composition.

[0090] Advantageously, the spray works without propellant gas.

[0091] The spray can be obtained by conventional formulation methods known to those skilled in the art. For example, the composition can be sprayed by a mechanical sprayer that pumps the composition into a container, bottle, or equivalent. The composition passes through a nozzle that can be directed directly to the desired application site. The nozzle can be chosen to apply the composition as a spray or a jet of droplets, according to techniques known to those skilled in the art. One of the advantages of applying the composition according to the invention by spray is that it avoids application to the fingers, which can cause pain upon contact and / or transmit infections, especially when the skin barrier is compromised.

[0092] The composition according to the invention can be sprayed close, i.e. a few centimeters from the skin or from further away, i.e. beyond 10 cm from the skin; it is interesting to note that the desired effects on the skin will be different depending on the spraying distance from the skin.

[0093] According to one embodiment of the invention, the sprayable composition of the invention shall be sprayed at close range, that is to say, less than 10 cm from the skin, preferably 5-6 cm from the skin, and even more preferably 3-4 cm from the skin. This close spraying shall produce a relatively solid gel-like layer on the skin, a few square centimeters in area, more or less thin depending on the quantity sprayed.

[0094] The composition according to the invention, by its thixotropic property, once sprayed on the skin, gradually and uniformly re-gels until it forms a stable layer, creating a "second skin effect".

[0095] For the purposes of this invention, "stable layer" means a layer that remains on the skin for more than one minute, preferably more than 5 minutes, and even more preferably more than 10 minutes.

[0096] This relatively solid layer protects the targeted area by acting locally with a cooling effect, while simultaneously modulating nociceptive pathways in the protected zone. This highly localized administration is perfectly suited for relieving acute skin pain, such as that caused by blows or insect bites, as well as post-procedure relief following minor surgical procedures like biopsies or skin excisions. Ideally, the application is performed immediately after the medical procedure, such as the blow or insect bite.

[0097] According to another embodiment of the invention, the sprayable composition of the invention shall be sprayed at a distance of more than 10 cm from the skin, preferably at more than 15 cm from the skin, and even more preferably at more than 20 cm from the skin. The composition of the invention, thus sprayed, shall not form a solid layer but shall remain in fine droplets.

[0098] The product is administered by spraying it from a distance of more than 5 cm from the skin to achieve a cooling effect, preferably more than 10 cm, more advantageously more than 15 cm, and even more preferably approximately 20 cm from the skin. This more diffuse spray will also produce a cooling effect, but over a larger area. This more diffuse application is perfectly suited to more chronic skin pain, particularly in inflammatory dermatoses, but also to pain affecting a larger area of ​​skin.

[0099] According to one embodiment of the invention, the spraying mechanism must be capable of delivering the same quantity of product at all times. The mechanisms for controlling the quantity of composition delivered by the spray are also known to those skilled in the art.

[0100] According to one embodiment of the invention, the cosmetic or dermatological composition according to the invention further comprises an extract of Uncaria Tomentosa vine.

[0101] The Peruvian liana, or Uncaria tomentosa, is a plant belonging to the Rubiaceae family. It is a climbing vine that can reach 20-30 m in length, with a main stem up to 25 cm in diameter. It has quadrangular branches, generally pubescent, and broadly oval-triangular stipules that are finely and densely pubescent on the outside.

[0102] The leaves are hairless or nearly hairless, opposite, with pubescent to pubescent undersides. The leaf blade is oval to oval-oblong, with a rounded base and an entire or crenate margin in the upper half. The spines are located at the base of the leaves, strongly curved, tomentose on young branches, and hairless on older ones. These spines help the plant climb trees, usually 20 to 40 meters high, hence the name "cat's claw."

[0103] The inflorescence bears reduced bracts with small heads 12 to 20 mm in diameter, and peduncles 1.5 to 4 cm long. The flowers are sessile with a tubular calyx and obtuse lobes. The sessile fruits are capsules, 0.8 to 1.2 cm long, pubescent on the outside. The seeds have two long, narrow wings.

[0104] There are 34 species d'Uncaria with medicinal properties.

[0105] Uncaria tomentosais a South American plant that was widely used by indigenous peoples, particularly in Peru. The roots or stem bark are used medicinally, both orally and topically. This plant is used to treat a wide range of conditions, including rheumatism, arthritis, gastric ulcers, fever, asthma, urinary tract infections, viral infections, and allergies. These indications involve an inflammatory process and / or an immune disorder. Clinically, the beneficial effects of Uncaria tomentosa against leukemia, tumors, ulcers, infections and arthritis.

[0106] Three classes of constituents play an important role in the activity of Uncaria tomentosa : alkaloids, polyhydroxylated triterpenes and polyphenols.

[0107] From a therapeutic point of view, the most important constituents in the stem bark d'UncariaThese are the indole alkaloids, especially those with a pentacyclic structure (pteropodine, 25% of the total alkaloid, isopteropodine, speciophylline, uncarine F, mitraphylline and isomitraphylline). From a quantitative point of view, the most important tetracyclic alkaloids are rynchophylline and isorynchophylline.

[0108] Among the sterols, β-sitosterol is predominant, followed by stigmasterol and campesterol. Several triterpenes have been isolated from the bark and stem of Uncaria tomentosa, ursolic acid, oleanolic acid, uncaric acid, floridic acid, two trihydroxy-ursenoic acids, dioxo-ursenoic acid, several quinovic acid glycosides, tomentosides A and B.

[0109] Among the polyphenols identified were tannins and procyanidins, as well as kaempferol and dihydrokaempferol. Flavonoids isolated included epicatechin and cinchonains Ia and Ib. Other compounds identified as belonging to the polyphenol class included protocatechuic, vanillic, caffeic, syringic, and ellagic acids, as well as p-coumaric acid derivatives.

[0110] From a pharmacological perspective, two main activities are well described: anti-inflammatory and analgesic activity. For the anti-inflammatory aspect, decoctions of the bark d'Uncaria inhibit the production of TNF α and, to a lesser extent, that of PGE 2 (Goncalves et al., 2005, Phytochemistry, 66(1), 89). The aqueous extract of the bark of Uncaria tomentosaexhibits anti-inflammatory activity that is thought to be due at least in part to a quinovic acid glycoside. This extract attenuates indomethacin-induced chronic intestinal inflammation in rats. It inhibits NF-κB activation by 65–85% and is active in arthritis, either alone or as an adjunct to traditional therapies for treating pain, stiffness, and inflammation. Comparing an aqueous extract and an 80% ethanolic extract of the bark, the anti-inflammatory activity was found to be significantly greater for the hydroalcoholic extract. Mitraphylline, a pentacyclic oxindolic alkaloid present in the chloroform extract of the bark of Uncaria has been evaluated in vivoon various cytokines that play a role in inflammation. It inhibits the release of interleukins 1α, 1β, 17 and TNF-α by 50% in the same way as dexamethasone. Mitraphylline reduces IL-4 production by 40%, unlike the corticosteroid which has no activity (Rojas-Duran et al., 2012, J.

[0111] Ethnopharmacol. 143(3), 801-804). A clinical study conducted over 52 weeks on 40 patients with rheumatoid arthritis, who received 3 times 20 mg of aqueous extract of Uncaria tomentosa A double-blind, placebo-controlled trial using a daily dose containing 73.5% pentacyclic alkaloids and no tetracyclic alkaloids showed significant improvement in symptoms (painful joints and morning stiffness). However, the treatment had no effect on swollen joints or on the patient's perception of their disease progression.

[0112] Regarding pain, an alkaloid fraction of Uncaria tomentosademonstrated antinociceptive activity in vivo following intraperitoneal administration (Jurgensen et al., 2005, Pharmacology, Biochemistry and Behaviour, 81:466-477). The main findings were suppression of acute capsaicin-induced pain and the response to abdominal acetic acid. With a formalin test, pain inhibition was found in both the early and late phases. One of the presumed mechanisms of action is the activation of 5-HT2 receptors. The alkaloids geissoschizine methyl ether and isorhynchophylline have shown 5-HT1A agonist and 5-HT2A / 2C antagonist activity.

[0113] The plant is exclusively sourced from organized harvesting in Peru. It takes three years for the vine to become productive. The aerial parts are harvested several times a year from the same plant, leaving approximately 50 cm of stem for regeneration. The bark is stripped at the harvest site and bundled into approximately 1-meter-long bundles. It is then dried in the sun on a concrete slab or a plastic sheet for four to five days, depending on the season.

[0114] According to one embodiment of the invention, the extract of Uncaria tomentosa is a liquid extract, more particularly a hydrophilic extract, more particularly an aqueous extract, and even more particularly a hydroalcoholic or hydroglycolic extract.

[0115] This extract can notably be obtained by extraction with at least one hydrophilic solvent, preferably with at least one aqueous solvent and even more preferably with at least one hydroalcoholic solvent.

[0116] Such an extract may be used as is (solution with the extraction solvent) or in the form of a concentrated extract or dry extract after partial or total evaporation of the extraction solvent.

[0117] According to a preferred embodiment of the invention, when the extract is a hydroalcoholic extract, the alcohol is evaporated and the resulting aqueous solution is stabilized by the addition of propylene glycol.

[0118] According to one embodiment of the invention, the cosmetic or dermatological composition according to the invention further comprises an oat extract.

[0119] Preferably, oat extract is obtained from oat seedlings, and preferably as described in application WO 2010 / 054879; as described in the same application WO 2010 / 054879, such oat extract exhibits anti-inflammatory activity.

[0120] For the purposes of this invention, "oat seedling" refers to oats before heading, i.e., at the post-germination stage (approximately 2 weeks to 2 months after germination), during the stem elongation stage up to and including heading. "Stem elongation" refers to the growth phase corresponding to the elongation of the stem and the emergence of the developing ear, prior to flowering. Secondary metabolites described in application WO 2010 / 054879 are components of an oat seedling extract: flavonoids and avenacoside-type saponins. This extract is characterized by the presence of 2 to 15% flavonoids and 0.2 to 2% avenacosides A and B.

[0121] The process for preparing oat extract can be as follows: drying and grinding of oat parts, preferably oat seedlings, extraction in organic solvent chosen from the group consisting of ketones, esters, C1 to C4 alcohols and mixtures in any miscible proportion of these solvents, and, centrifugation or filtration.

[0122] Advantageously, the organic solvent of the process is chosen from the group consisting of acetone, methyl ethyl ketone, methyl isobutyl ketone, ethyl acetate, a C1 to C4 alcohol and a mixture in any miscible proportion of these solvents.

[0123] The pomace obtained by the extraction step is then separated from the extract by centrifugation or filtration and the solution can be more or less concentrated until a dry extract is obtained.

[0124] According to one embodiment of the invention, a carrier may be added during the drying step in mass proportions relative to the extracted dry matter ranging from 1 to 75%. The carrier may be a sugar such as maltodextrin, lactose, silica, or any other cosmetically or dermatologically acceptable carrier.

[0125] In another embodiment of the invention, the solution is concentrated so as to obtain a wort comprising 60 to 80% dry matter, and preferably 70% dry matter, by weight relative to the total weight of the wort.

[0126] According to another embodiment, the invention relates to a cosmetic or dermatological composition for topical application as described above for its soothing, calming and / or anti-irritant use.

[0127] According to another embodiment, the invention relates to a cosmetic or dermatological composition for topical application as described above for its use in the prevention and / or treatment of cutaneous neurogenic inflammation.

[0128] In particular, the prevention and / or treatment of neurogenic cutaneous inflammation includes, or consists of, the protection and / or treatment of irritated or fragile skin.

[0129] According to another embodiment, the invention relates to a cosmetic or dermatological composition for topical application as described above for its use in the prevention and / or treatment of inflammatory dermatoses selected from atopic dermatitis, eczema and psoriasis.

[0130] The cosmetic or dermatological composition for topical application as described above may be useful for modulating nociceptive pathways.

[0131] According to another embodiment, the invention relates to a cosmetic or dermatological composition for topical application as described above for use in the prevention and / or treatment of itching sensations and / or skin pain.

[0132] According to a particular embodiment of the invention, itching and / or skin pain are due to inflammatory dermatoses selected from atopic dermatitis, eczema and psoriasis.

[0133] According to another particular embodiment of the invention, the itching and / or skin pain is due to a sting, a blow, or a medical or surgical procedure, in particular an excision.

[0134] The compositions according to the invention are useful for preventing and / or treating sensations of itching and / or skin pain, in particular itching and / or skin pain due to inflammatory dermatosis, sting, blow or medical or surgical procedure.

[0135] The compositions according to the invention are useful for relieving, soothing or calming irritated skin and / or fragile skin and / or painful skin.

[0136] In particular, the soothing, calming, ultra-calming or relieving effect includes or consists of a reduction in sensations of skin discomfort.

[0137] In particular, the modulation of nociceptive pathways includes or consists of a reduced unpleasant cutaneous sensation.

[0138] The cosmetic or dermatological composition for topical application as described above is useful for the manufacture of a pharmaceutical or dermatological composition intended to soothe, calm and / or limit skin irritation.

[0139] The cosmetic or dermatological composition for topical application as described above is useful for the manufacture of a pharmaceutical or dermatological composition intended to prevent and / or treat neurogenic cutaneous inflammation.

[0140] The cosmetic or dermatological composition for topical application as described above is useful for the manufacture of a pharmaceutical or dermatological composition intended to prevent and / or treat selected inflammatory dermatoses from atopic dermatitis, eczema and psoriasis.

[0141] The cosmetic or dermatological composition for topical application as described above is useful for the manufacture of a pharmaceutical or dermatological composition intended to modulate nociceptive pathways.

[0142] The cosmetic or dermatological composition for topical application as described above is useful for the manufacture of a pharmaceutical or dermatological composition intended to prevent and / or treat sensations of itching and / or skin pain, in particular itching and / or skin pain due to an inflammatory dermatosis, a sting, a blow or a medical or surgical procedure.

[0143] A method for soothing, calming and / or limiting skin irritation includes administering to a patient in need an effective amount of a cosmetic or dermatological composition for topical application as described above.

[0144] A method for preventing and / or treating neurogenic cutaneous inflammation includes administering to a patient in need an effective amount of a cosmetic or dermatological composition for topical application as described above.

[0145] A method for preventing and / or treating inflammatory dermatoses selected from atopic dermatitis, eczema and psoriasis, includes administering to a patient in need an effective amount of a cosmetic or dermatological composition for topical application as described above.

[0146] One method for modulating nociceptive pathways includes administering to a patient in need an effective amount of a cosmetic or dermatological composition for topical application as described previously.

[0147] A method for preventing and / or treating sensations of itching and / or skin pain, especially itching and / or skin pain due to inflammatory dermatosis, sting, blow or medical or surgical procedure, includes administering to a patient in need an effective amount of a cosmetic or dermatological composition for topical application as described above.

[0148] These topical compositions can be used daily, once or several times a day, without limitation on the duration of treatment.

[0149] A cosmetic process for providing a soothing or calming topical action consists of applying an effective amount of the topical composition according to the invention to the area of ​​skin concerned. Description of the figures

[0150] There figure 1represents the measurement of the viscosity (η, on the ordinate, expressed in Pa.s) of the composition according to the invention over time (t, on the abscissa, expressed in seconds). Examples Example 1: Example of a composition according to the invention

[0151] Table 1 INCI designation Percentage by weight Water QSP 100% Caprylic / capric triglyceride 2-20 % Glycerin 2-10 % Crosslinked Polymer Acrylates / C10-30 Alkyl Acrylate 0,10-0,25 % Oat leaf Avena Sativa / stem extract 0,1-1 % Benzoic acid 0,1-0,5 % Caprylyl Glycol 0,2-0,5 % Carbomer 0,10-0,25 % Propylene Glycol 0,1-10 % Scleroglucan gum 0,01-0,15 % Sodium hydroxide 0,1-0,5 % Extract from Uncaria Tomentosa 0,1-3 % Example 2: Sensory profile of formulas according to the invention

[0152] The objective of this test is to compare the sensory characteristics of two formulas according to the invention.

[0153] The two formulas tested are: formula A corresponds to that of example 1, formula B is the same but without extract of Uncaria Tomentosa. Methodology

[0154] The evaluation conditions are as follows: At the beginning of each session, the temperature and humidity of the room are recorded, the acceptable temperature being 22°C ± 2°C. Each cabin is equipped with a computer, a sink with regular water flow, standardized water temperature and lighting.

[0155] The test is conducted by 15 women trained in sensory analysis techniques for topical products; these are expert subjects who have completed and passed their training period, according to the NF_ISO_8586:2012 standard. The sensory analysis expert panel is composed of volunteers with up-to-date medical records. The expert subjects have no medical contraindications to participating in a sensory analysis test. They have all types of healthy skin. Panelists are asked to arrive at the session without having applied any leave-on products to their face and forearms (makeup, perfume, creams, lotions, etc.), smoked, drunk coffee, or used menthol products during the hour preceding the test.

[0156] The product, in the form of a body lotion, is applied to the forearms, one formula per forearm. The products are measured out during the same session. They are dispensed at a rate of 0.5 ml per application using syringes or automatic pipettes adapted to the required quantity of product.

[0157] Descriptors used in the study: Phase (1) at application Ease of spreading: the product's ability to spread easily on the skin Penetration speed: how quickly the product penetrates the skin Coolness: a sensation of decreased skin temperature Wetness: the product feels damp between the fingers Oily: like cooking oil between the fingers Stickiness: the finger or hand adheres to the application area Crunchy: the product doesn't stick properly between the fingers Phase (2) 5 minutes after application Coolness: a sensation of decreased skin temperature Tightness: a feeling of tightness Shine: the skin's ability to reflect light Oily: like cooking oil between the fingers Resistant: resistance to the hand moving across the application area Stickiness: the finger or hand adheres to the application area Film-forming: a film remains on the hand Powdery feel: like peach skin (blur effect) Suppleness:Skin elasticity. Plump skin: skin thickness when pinched and tapped. Fuzzy: formation of small particles on the application area. Phase (3) 30 minutes after application

[0158] Same, but without the freshness.

[0159] The descriptors were learned during prior training. They are explained orally at the beginning of each session. The computer questionnaire (FIZZ Acquisition 2.51 software, Biosystemes) displays unstructured analog measurement scales from 0 to 100 for each descriptor at different phases on the computer screen. For each descriptor, the intensities of the two products are quantified on two scales, one corresponding to the product applied on the left (formula A), the other to the product applied on the right (formula B).

[0160] At the end of each phase, subjects must indicate via the computer questionnaire if they experience any adverse reactions such as tingling, heat, redness, itching, burning sensation and pulling or others to be specified, indicate the intensities (low intensity, medium intensity, intense and very intense) and their evolution (increase, decrease, spontaneous cessation during the evaluation or resolution after normal rinsing of the products at the end of the session).

[0161] Statistical tests were performed using FIZZ software, version 2.60 (Biosystemes). The analysis was conducted descriptor by descriptor, with means represented as radar charts, and the significance of the differences between the two formulas was assessed using a Student's t-test.

[0162] The results are summarized in Table 2.

[0163] The inventors thus clearly demonstrate that a composition based on the three gelling agents according to the invention produces a cooling effect perceived by subjects experienced in this type of sensory test. This cooling effect is even rated at 70 on a scale of 0 to 100, with 0 representing the absence of a cooling effect and 100 representing a maximum perceived cooling effect.

[0164] Few differences were observed between these two formulas. For all 15 subjects, the greatest differences were found in the descriptors shown in Table 2 below: Table 2 Formula A Formula B Difference Attribute Mey SD Mey SD Mey SD Stat Freshness 1 63,21 28,19 68,86 21,61 5,64 10,75 0,07 Voltage 2 10,79 23,0 15,36 24,34 4,57 7,67 0,04 Brilliance 2 29,71 28,44 38,07 29,07 8,36 17,09 0,09 Plump Skin 32,29 24,65 37,71 26,25 5,43 10,84 0,08

[0165] Under the conditions of this study, the sensory characteristics of the two formulas were very similar. Five minutes after application, formula A produced fewer sensations of tightness, but this difference was small. Other sensations were not perceived as significantly different.

[0166] Therefore, in the context of this study, comparing the perceived intensity of freshness between the two formulas, it is important to note that formula A, which contains an extract of a Peruvian liana known to induce a cooling effect, does not stand out from formula B, which does not contain this extract. This sensation of freshness is indeed due to the combination of carbomer, a natural polysaccharide, and a hydrophobically modified copolymer. Example 3: Demonstration that the composition according to the invention is thixotropic

[0167] The composition tested is that of example 1.

[0168] The method consists of measuring the viscosity of the composition over time. Viscosity measures a fluid's resistance to flow. A rheometer, the Thermo Fisher Haake MARS60, is used for this purpose. The study was conducted at 22°C, and a 1° flat cone was used as the moving part. Three stages were performed. The first stage involved rotation at 0.1 s⁻¹ for 300 seconds, resulting in a very low stress that mimics the viscosity at rest. The second stage involved rotation at 60 s⁻¹ for 30 seconds (a very high stress); this stage can be likened to pumping the product. Finally, the third stage involved rotation again at 0.1 s⁻¹ for 300 seconds, allowing visualization of the reaction of the tested composition.

[0169] The results are presented on the Figure 1It follows that the composition according to the invention is thixotropic since its viscosity slowly recovers after being sheared. Indeed, the slower this recovery, the more pronounced the thixotropic effect. The inventors have therefore perfectly demonstrated the thixotropic nature of the composition according to the invention. Example 4: Clinical study, efficacy in use on irritated skin in adults of the composition described in example 1.

[0170] The study was conducted on 33 patients, men and women over 18 years of age, with skin phototypes I to IV. All these patients presented with facial and / or body irritations related either to external factors (friction, detergents, climate) for 11 subjects, or to post-shave irritation for 11 subjects, or to sunburn for 11 subjects. All these patients reported discomfort related to these irritations, which they perceived as painful, with a score of 3 on a pain scale ranging from 0 to 10 (a score of 0 corresponding to no pain and a score of 10 corresponding to the worst imaginable pain).

[0171] The study is conducted over 22 days. The instructions for applying the composition according to the invention are to shake and spray the product 20 cm from the irritated area and massage if necessary, and to use it up to 6 times a day.

[0172] During the first day (J1) of the clinical study, a dermatological evaluation is performed before and after application: physical signs: erythema, edema, desquamation, dry skin, vesicle, papule, others; functional signs related to skin irritation: burning sensation, sensation of heat, itching, tightness, tingling.

[0173] Alongside this assessment, there is also a dermatology quality of life questionnaire, a measurement of the soothing effect on a scale of 0 to 3 (0 corresponding to no soothing effect; 3 corresponding to a significant soothing effect) and a measurement of the intensity of discomfort sensations perceived as painful on a VAS (Visual Analog Scale, a scale that measures a subjective feeling of discomfort sensations).

[0174] All these assessments are repeated on day 3, day 8 and day 22 with an additional acceptability questionnaire (concerning a cooling effect and an ultra-calming effect).

[0175] An initial comparison is made for each subject at each time point before and after application; this is the immediate effect. A second comparison is evaluated for each subject before treatment, that is, before application of Day 1 versus after application at each time point; this is the cumulative effect. A time point is defined as one application of the composition according to the invention, regardless of the day of application and regardless of the number of applications performed per day.

[0176] It should be noted that after 21 days of use on the areas under study, with the composition according to the invention applied 1 to 6 times daily, no subject reported any functional or physical symptoms during the study. No subject presented any new symptoms on day 22, nor did any present any worsening symptoms compared to day 1 (before application). The tolerability of the composition according to the invention is therefore considered excellent.

[0177] The results of the physical signs are shown in Table 3 below: Each subject at each visit receives a score from 0 to 4 (0 for no signs, 1 for very mild, 2 for mild, 3 for moderate, and 4 for severe) during a dermatological assessment of erythema, desquamation, and dryness of the skin. All these scores are averaged. Table 3 Day Erythema Desquamation Drought J1 T0 1,8 0,7 0,8 J1 1,7 0,3 0,3 J3 0,8 0,2 0,2 J8 0,3 0,0 0,1 J22 0,2 0,0 0,1 J1 T0: before the first application of J1.

[0178] These results demonstrate that the composition according to the invention significantly improves physical signs from the first application and that this improvement intensifies as the composition according to the invention is used during the 3 weeks of study.

[0179] The results of the functional signs are shown in Table 4 below: Each subject at each visit receives a score from 0 to 4 (0 for no signs, 1 for very mild, 2 for mild, 3 for moderate, and 4 for severe) during a dermatological assessment of burning, itching, tingling, and pulling sensations. All these scores are averaged. Table 4 Day Burning sensation Itching Tingling Torsion J1 T0 1,0 1,2 0,6 0,2 J1 0,4 0,5 0,2 0,1 J3 0,1 0,2 0,0 0,0 J8 0,0 0,0 0,0 0,0 J22 0,0 0,0 0,0 0,0 J1 T0: before the first application of J1.

[0180] These results demonstrate that the composition according to the invention significantly improves functional signs from the first application and as the composition according to the invention is used during the 3 weeks of study.

[0181] The results of the evaluation of the immediate soothing effect carried out using the dermatology quality of life questionnaire are shown in Table 5 below: Table 5 J1T0 J1 J3T0 J3 J8T0 J8 J21T0 J21 Score (0-3) 0 1,27 0,24 1,64 0,36 1,91 0,79 2,39

[0182] The inventors thus clearly highlight an immediate soothing effectiveness, with a significant difference between before and after application of the composition according to the invention.

[0183] The effect of the composition according to the invention on quality of life, by reducing sensations of discomfort perceived as painful, is also very positive. Indeed, the dermatology quality of life questionnaire demonstrated that on day 1, 82% of subjects indicated that sensations of discomfort had a moderate to significant impact on their quality of life. On day 3, there was a decrease in the impact on quality of life, with 55% of subjects indicating that sensations of discomfort had a moderate to significant impact on their quality of life. On day 8, an even more marked decrease in the impact on quality of life was observed, with only 33% of subjects indicating that sensations of discomfort had a moderate to significant impact on their quality of life. On day 22, a large majority of subjects (82%) reported a significant improvement in their quality of life. The inventors thus demonstrate that the subjects' quality of life improves with continued use of the composition according to the invention.

[0184] The cooling effect experienced (rated from 0 to 10 in the clinical study acceptability questionnaire) by the subjects (in %) when applying the composition according to the invention is summarized in Table 6 below: Table 6 Score (0-10) J3 J8 J22 Percentage of subjects 0-4 3,0 % 9,1 % 9,1 % 5 3,0 % 3,0 % 3,0 % 6-7 15,2 % 9,1 % 0,0 % 8-10 78,8 % 78,8 % 87,9 %

[0185] The cooling effect is therefore felt (score > 5) by approximately 90% of patients at the end of this study.

[0186] The immediate ultra-calming effect is also assessed as part of the clinical study acceptability questionnaire and is summarized in Table 7 below (a score of 0 corresponds to no immediate ultra-calming effect and a score of 10 corresponds to a significant immediate ultra-calming effect): Table 7 Score (0-10) J3 J8 J22 Percentage of subjects 0-4 9,1 % 6,1 % 6,1 % 5 0,0 % 3,0 % 3,0 % 6-7 21,2 % 18,2 % 12,1 % 8-10 69,7 % 72,7 % 78,8 %

[0187] Thus, the immediate ultra-calming effect is felt (score > 5) by a majority of subjects throughout the study; indeed, more than 90% of subjects give a score of at least 6 / 10 to judge this effect.

[0188] In conclusion to this clinical study conducted on 33 subjects with irritated skin, the inventors demonstrate the effectiveness of the composition according to the invention on all the parameters analyzed. Example 5: Clinical study, efficacy in use on the skin of patients with psoriasis of the composition described in example 1.

[0189] Information about the study was provided to each patient before the start of the study. This information was accessible, understandable, and tailored to each trial participant. It was provided orally and then in a written document. Each patient thus gave their informed consent.

[0190] The study was conducted on 30 patients, men and women, aged 26 to 60 years (mean age 51 years), with skin phototypes I to IV. All patients presented with facial and / or body irritation related to psoriasis. For all patients, psoriasis had to affect less than 10% of the body surface area and have a PASI (Psoriasis Area Severity Index) score < 10. The aim of this study was to evaluate: 1 / the dermatological tolerance of the composition according to the invention and 2 / the effectiveness on the improvement of physical and functional signs.

[0191] The study is conducted over 21 days ± 48 hours, without interruption. The instructions for applying the composition daily according to the invention are to shake and spray the product 20 cm from the irritated area and massage if necessary, and to use it 1 to 6 times a day.

[0192] The tolerance of the composition according to the invention is assessed by the dermatologist himself. For each subject, the dermatological evaluation is carried out during the visits, i.e. on Day 1 (D1, before and 10 to 30 minutes after application), at the second visit on Day 3 (D3), at the third visit on Day 8 (D8 ± 1 day) and at the final visit after 21 days of application (D22 ± 2 days).

[0193] The following signs are assessed: Physical signs: erythema, edema, desquamation, dry skin, vesicles, papules, other. Functional signs reported by the patient: burning sensation, heat sensation, itching, tightness, tingling sensation, other.

[0194] For each sign, the intensity is reported with the following scale: 0: no sign; 1: very mild; 2: mild; 3: moderate; 4: severe; then the location, duration and frequency.

[0195] An overall assessment of dermatological tolerance is made taking into account all criteria; it is characterized by 5 levels Poor Moderate Good Very good Excellent (no physical or functional signs reported by subjects).

[0196] The efficacy of the composition according to the invention is evaluated by the improvement of physical and functional signs. The dermatologist records the score on day 1 (before and after application), day 3, day 8, and day 22 of functional signs related to skin irritation on a scale of 0 to 4 (0: no irritation; 1: very mild; 2: mild; 3: moderate; 4: severe). The physical and functional signs are the same as those described for the tolerance assessment. Results

[0197] It should be noted that after 21 days of using the composition according to the invention, applied 1 to 6 times daily, no subject reported any physical or functional symptoms during the study. No subject presented any new symptoms on day 22, nor did any subject present any worsening symptoms compared to day 1 (before application). The tolerability of the composition according to the invention is therefore considered excellent.

[0198] The results of the physical signs are shown in Table 8 below. Table 8 Intensity score ± esm Statistics vs J1To p Erythema J1 T0 2,45 ± 0,11 - Day 1 / 10-30 min 2,36 ± 0,10 0,083 J3 1,94 ± 0,09 <0,001 J8 1,61 ± 0,10 <0,001 J22 1,32 ± 0,14 <0,001 Edema J1 T0 1,06 ± 0,06 - Day 1 / 10-30 min 1,06 ± 0,06 1,000 J3 0,64 ± 0,13 0,034 J8 0,36 ± 0,13 0,004 J22 0,29 ± 0,13 0,002 Drought J1 T0 1,79 ± 0,11 - Day 1 / 10-30 min 0,56 ± 0,09 <0,001 J3 0,91 ± 0,10 <0,001 J8 0,81 ± 0,08 <0,001 J22 0,11 ± 0,09 <0,001 Desquamation J1 T0 1,73 ± 0,10 - Day 1 / 10-30 min 0,64 ± 0,11 <0,001 J3 0,81 ± 0,12 <0,001 J8 0,45 ± 0,09 <0,001 J22 0,29 ± 0,08 <0,001 Papule J1 T0 2,00 - Day 1 / 10-30 min 2,00 - J3 0,00 - J8 0,00 - J22 0,00 -

[0199] The comparison between the different time points is performed using a statistical analysis of ranks with the Wilcoxon-Mann-Whitney test. Significance is reached when p < 0.05. esm: standard error of the mean.

[0200] For the criterion of presence of papule, no statistical test is carried out, too small a sample size.

[0201] For the criteria of presence of erythema or edema, a statistically significant decrease in average scores is observed from day 3 and persists on day 22, compared to day 1 before application of the composition according to the invention. The reduction appears more pronounced for erythema.

[0202] For dry skin and desquamation, very significant reductions (p<0.001) in average scores are observed from the first application and persist throughout the duration of treatment.

[0203] The results of the functional signs are shown in Table 9 below. Table 9 Intensity score ± esm Statistics vs J1To p Burning sensation J1 T0 2,00 ± 0,00 - Day 1 / 10-30 min 0,67 ± 0,33 0,102 J3 0,33 ± 0,33 0,102 J8 0,33 ± 0,33 0,102 J22 1,00 ± 0,58 0,180 Sensation of warmth J1 T0 2,00 - Day 1 / 10-30 min 2,00 - J3 1,00 - J8 0,00 - J22 0,00 - Itching J1 T0 2,91 ± 0,08 - Day 1 / 10-30 min 1,97 ± 0,14 <0,001 J3 1,75 ± 0,15 <0,001 J8 1,47 ± 0,12 <0,001 J22 1,03 ± 0,14 <0,001 A pulling sensation J1 T0 2,33 ± 0,33 - Day 1 / 10-30 min 0,67 ± 0,67 0,102 J3 0,67 ± 0,67 0,102 J8 0,33 ± 0,33 0,083 J22 0,33 ± 0,33 0,083 Tingling sensation J1 T0 2,50 ±1 0,22 - Day 1 / 10-30 min 1,83 ± 0,31 0,102 J3 1,17 ± 0,31 0,038 J8 1,17 ± 0,31 0,038 J22 0,83 ± 0,40 0,039

[0204] The comparison between the different time points is performed using a statistical analysis of ranks with the Wilcoxon-Mann-Whitney test. Significance is reached when p < 0.05. esm: standard error of the mean.

[0205] For the criterion of perceived warmth, no statistical test is carried out, too small a sample size.

[0206] The average score for the burning sensation tends to decrease after application of the composition according to the invention, but this reduction does not reach the threshold of significance. The same is true for the sensation of pulling.

[0207] The tingling sensation, however, is significantly reduced from day 3 and persists until day 22.

[0208] Itching is greatly reduced by the application of the composition according to the invention, the average score is statistically reduced (p<0.001) from the first application and throughout the treatment.

[0209] In conclusion, in this study of 30 patients, the composition according to the invention is extremely well tolerated by patients with psoriasis. It is effective in improving the physical signs present in patients (erythema, edema, dryness, and scaling) and soothes itching. Its effectiveness is rapid, occurring within 10 to 30 minutes after application, and persists throughout the duration of treatment. Example 6: Clinical study, efficacy in use on the skin of patients with atopic dermatitis of the composition described in example 1.

[0210] Information about the study was provided to each patient before the start of the study. This information was accessible, understandable, and tailored to each trial participant. It was provided orally and then in a written document. Each patient thus gave their informed consent.

[0211] The study was conducted on 33 patients, men and women, aged 22 to 61 years (mean age 43 years), with skin phototypes I to IV. All subjects had atopic dermatitis as defined by the UK Working Party's Diagnostic Criteria for Atopic Dermatitis. They had a SCORAD score of 15 to 25 and were using only an emollient, which they continued to apply once daily. The subjects experienced skin discomfort, perceived as painful and related to atopic dermatitis. To be included in the study, the pain level had to reach at least a score of 3 on a visual analog scale of 0 to 10.

[0212] The aim of this study is to evaluate, as in example 5: 1 / the dermatological tolerance of the composition according to the invention and 2 / the effectiveness on the improvement of physical and functional signs.

[0213] The study is conducted over 21 days ± 48 hours, without interruption. The instructions for applying the composition daily according to the invention are to shake and spray the product 20 cm from the irritated area and massage if necessary, and to use it 1 to 6 times a day.

[0214] The administration protocol, tolerance and efficacy criteria are the same as those described in example 5.

[0215] It should be noted that after 21 days of using the composition according to the invention, applied 1 to 6 times daily, some reactions occurred, but the majority were fleeting and of mild intensity. Furthermore, the reactions generally occurred within the first few days and resolved after the first week of use. While signs of discomfort were reported, only one physical symptom was noted. The tolerability of the composition according to the invention is therefore considered good, even though the composition was tested on a panel of subjects with atopic dermatitis, who thus have sensitive and irritated skin.

[0216] The results of the physical signs are shown in Table 10 below. Table 10 Intensity score ± esm Statistics vs J1To p Erythema J1 T0 0,6 ± 0,1 - Day 1 / 10-30 min 0,5 ± 0,1 0,500 J3 0,4 ± 0,1 0,0156 J8 0,3 ± 0,1 0,0156 J22 0,3 ± 0,1 0,0078 Edema J1 T0 0,0 ± 0,0 - Day 1 / 10-30 min 0,0 ± 0,0 ND J3 0,0 ± 0,0 ND J8 0,0 ± 0,0 ND J22 0,0 ± 0,0 ND Drought J1 T0 2,5 ± 0,1 - Day 1 / 10-30 min 1,3 ± 0,1 <0,001 J3 1,0 ± 0,1 <0,001 J8 0,7 ± 0,1 <0,001 J22 0,2 ± 0,1 <0,001 Desquamation n J1 T0 2,1 ± 0,1 - Day 1 / 10-30 min 0,6 ± 0,1 <0,001 J3 0,3 ± 0,1 <0,001 J8 0,1 ± 0,0 <0,001 J22 0,0 ± 0,0 <0,001 Papule J1 T0 0,5 ± 0,1 - Day 1 / 10-30 min 0,4 ± 0,1 1,000 J3 0,3 ± 0,1 0,125 J8 0,2 ± 0,1 0,0313 J22 0,1 ± 0,1 0,0156

[0217] The comparison between the different time points is performed using a statistical analysis of ranks with the Wilcoxon-Mann-Whitney test. Significance is reached when p < 0.05. esm: standard error of the mean. No statistical test is performed for the presence of edema, due to the small sample size.

[0218] Immediately after application of the composition according to the invention, statistically significant reductions in skin dryness and desquamation were observed in virtually all patients. After three days of application, a 35% reduction in erythema was observed in half of the patients, an 88% reduction in desquamation was found in all patients, and less skin dryness was also noted. These results persisted throughout the treatment and were even further improved, as the overall physical signs were reduced by 80% for all patients.

[0219] The results of the functional signs are shown in Table 11 below. Table 11 Intensity score ± esm Statistics vs J1To p Burning sensation J1 T0 0,7 ± 0,2 - Day 1 / 10-30 min 0,5 ± 0,2 0,3125 J3 0,2 ± 0,1 0,001 J8 0,1 ± 0,1 <0,001 J22 0,0 ± 0,0 <0,001 Sensation of warmth J1 T0 0,4 ± 0,1 - Day 1 / 10-30 min 0,3 ± 0,1 0,500 J3 0,0 ± 0,0 0,0313 J8 0,0 ± 0,0 0,0625 J22 0,0 ± 0,0 0,0625 Itching J1 T0 1,6 ± 0,2 - Day 1 / 10-30 min 0,8 ± 0,1 <0,001 J3 0,0 ± 0,0 <0,001 J8 0,0 ± 0,0 <0,001 J22 0,0 ± 0,0 <0,001 A pulling sensation J1 T0 1,7 ± 0,2 - Day 1 / 10-30 min 0,6 ± 0,1 <0,001 J3 0,0 ± 0,0 <0,001 J8 0,0 ± 0,0 <0,001 J22 0,0 ± 0,0 <0,001 Tingling sensation J1 T0 0,5 ± 0,2 - Day 1 / 10-30 min 0,2 ± 0,1 0,0078 J3 0,1 ± 0,0 0,0020 J8 0,0 ± 0,0 0,0020 J22 0,0 ± 0,0 0,0039

[0220] The comparison between the different time points is performed using a statistical analysis of ranks with the Wilcoxon-Mann-Whitney test. Significance is reached when p < 0.05. esm: standard error of the mean.

[0221] Immediately after application of the composition according to the invention, a statistically significant reduction in itching was noted in almost all patients. Similarly, marked and significant reductions in the sensations of pulling and tingling were observed in almost all those tested. After 3 days of treatment, all functional symptoms were significantly reduced; for example, a 98% reduction in itching was recorded. All these symptoms were significantly reduced throughout the treatment period, although the significance threshold for the sensation of heat was not quite reached (p=0.06). After 22 days of treatment, itching, pulling, and tingling were completely absent in all patients, demonstrating the efficacy of the composition according to the invention.

[0222] In conclusion, in this study of 33 patients, the composition according to the invention is well tolerated by patients with atopic dermatitis. It is effective in improving the patients' physical and functional symptoms. Its efficacy is rapid, occurring within 10 to 30 minutes after application, and persists throughout the duration of treatment. Example 7: Clinical study, efficacy in use on the skin of patients experiencing pain in their hands due to irritation, of the composition described in example 1.

[0223] Information about the study was provided to each patient before the start of the study. This information was accessible, understandable, and tailored to each trial participant. It was provided orally and then in a written document. Each patient thus gave their informed consent.

[0224] The study was conducted on 16 patients, men and women, aged 26 to 58 years (mean age 47 years), with skin phototypes III to IV. All subjects presented with eczema on their hands, causing a sensation of skin discomfort perceived as painful. The patients were not receiving any treatment at the time of inclusion. To be included, each patient had to have a pain sensation that reached a score of at least 3 on a visual analog scale of 0 to 10.

[0225] The experimental protocol is the same as that of examples 5 and 6.

[0226] The dermatological tolerance of the composition according to the invention is tested; the tolerance criteria are the same as those described in example 5.

[0227] The soothing efficacy of the composition according to the invention is evaluated on a scale of 0 to 3 (0: none; 1: moderate; 2: good; 3: very good). Its ability to reduce the intensity of skin discomfort perceived as distressing is measured using a visual analog scale of 0 to 10. Results

[0228] It should be noted that after 21 days of using the composition according to the invention, applied 1 to 6 times daily, no subject reported any physical or functional symptoms during the study. No subject presented any new symptoms on day 22, nor did any subject present any worsening symptoms compared to day 1 (before application). The tolerability of the composition according to the invention is therefore considered excellent, even when applied to very irritated skin.

[0229] The soothing efficacy is summarized in Table 12 below. Table 12 Kinetic Average score ± esm Statistic p-value J1-J1T0 1,38 ± 0,13 <0,001 J2-J1T0 1,44 ± 0,13 <0,001 J3-J1T0 1,44 ± 0,13 <0,001 J4-J1T0 1,50 ± 0,13 <0,001 J5-J1T0 1,69 ± 0,18 <0,001 J6-J1T0 1,63 ± 0,15 <0,001 J7-J1T0 1,69 ± 0,15 <0,001 J8-J1T0 1,81 ± 0,16 <0,001 J9-J1T0 1,88 ± 0,18 <0,001 J10-J1T0 1,94 ± 0,17 <0,001 J11-J1T0 2,00 ± 0,18 <0,001 J12-J1T0 2,00 ± 0,18 <0,001 J13-J1T0 2,00 ± 0,18 <0,001 J14-J1T0 2,00 ± 0,18 <0,001 J15-J1T0 2,00 ± 0,18 <0,001 J16-J1T0 2,00 ± 0,18 <0,001 J17-J1T0 2,06 ± 0,17 <0,001 J18-J1T0 2,25 ± 0,19 <0,001 J19-J1T0 2,25 ± 0,19 <0,001 J20-J1T0 2,25 ± 0,19 <0,001 J21-J1T0 2,25 ± 0,19 <0,001

[0230] The comparison between the different time points (relative to J1T0, before application) is performed using a statistical analysis of ranks with the Wilcoxon-Mann-Whitney test. Significance is reached when p < 0.05. esm: standard error of the mean.

[0231] Under these experimental conditions, after application 1 to 6 times per day of the composition according to the invention, a significant immediate soothing efficacy is observed from the first use of the product on day 1 and continuously up to 21 days of application.

[0232] The results on the immediate effect of applying the composition according to the invention are presented in Table 13 below. Table 13 Kinetic Average score ± esm Statistic p-value % of subjects with an improvement J1imm - J1T0 -1,38 ± 0,26 <0,001 81 J2imm - J2T0 -1,00 ± 0,30 0,0048 75 J3imm - J3T0 -1,13 ± 0,27 <0,001 81 J4imm - J4T0 -1,00 ± 0,27 0,0027 75 J5imm - J5T0 -1,13 ± 0,36 0,0074 75 J6imm - J6T0 -1,19 ± 0,33 0,0027 75 J7imm -J7T0 -1,19 ± 0,33 0,0027 69 J8imm - J8T0 -1,13 ± 0,36 0,0074 75 J9imm - J9T0 -0,94 ± 0,40 0,0371 63 J10imm - J10T0 -0,75 ± 0,34 0,0410 56 J11imm - J11T0 -0,56 ± 0,24 0,0339 56

[0233] The comparison between the different time points (relative to J1T0, before application) is performed using a statistical analysis of ranks with the Wilcoxon-Mann-Whitney test. Significance is reached when p < 0.05. esm: standard error of the mean.

[0234] A significant immediate effect on reducing the sensation of discomfort perceived as painful is demonstrated from the first day and during the first 11 days of application in a large proportion of patients.

[0235] The cumulative effect is summarized in Table 14 below. Table 14 Kinetic Average score ± esm Statistic p-value % of subjects with an improvement J3T0 - J1T0 -1,25 ± 0,63 0,0469 38 J4T0 - J1T0 -1,56 ± 0,66 0,0039 56 J5T0 - J1T0 -2,00 ± 0,67 0,0020 63 J6T0 - J1T0 -2,31 ± 0,70 0,0020 63 J7T0 - J1T0 -2,56 ± 0,71 0,0027 69 J8T0 - J1T0 -3 00 ± 0,72 <0,001 81 J9T0 - J1T0 -3,50 ± 0,78 <0,001 81 J10T0 - J1T0 -3,88 ± 0,74 <0,001 88 J11T0 - J1T0 -4,13 ± 0,71 <0,001 88 J12T0 -J1T0 -4,69 ± 0,72 <0,001 88 J13T0 - J1T0 -4,69 ± 0,72 <0,001 94 J14T0 - J1T0 -4,94 ± 0,72 <0,001 94 J15T0 - J1T0 -5,06 ± 0,69 <0,001 94 J16T0 - J1T0 -5,19 ± 0,71 <0,001 94 J17T0 - J1T0 -5,38 ± 0,73 <0,001 94 J18T0 - J1T0 -5,50 ± 0,72 <0,001 88 J19T0 - J1T0 -5,56 ± 0,70 <0,001 94 J20T0 - J1T0 -5,75 ± 0,73 <0,001 94 J21T0 - J1T0 -5,88 ± 0,72 <0,001 94

[0236] The comparison between the different time points (relative to JT0, before application) is performed using a statistical analysis of ranks with the Wilcoxon-Mann-Whitney test. Significance is reached when p < 0.05. esm: standard error of the mean.

[0237] A statistically significant cumulative effect on reducing the sensation of discomfort perceived as painful is clearly demonstrated from day 3 and throughout the duration of the treatment.

[0238] In conclusion, in this study of 16 patients, the composition according to the invention is extremely well tolerated by patients with eczema. It demonstrates immediate and lasting soothing efficacy throughout the treatment period. An effect on reducing the sensation of discomfort perceived as painful is also demonstrated.

Claims

1. Cosmetic or dermatological composition in the form of an emulsion for topical application, comprising: - an oil phase; and - an aqueous phase comprising a carbomer, a natural polysaccharide and a hydrophobically modified crosslinked acrylic or methacrylic copolymer; said composition comprising from 0.10 to 0.25%, preferably from 0.15 to 0.20%, by weight of carbomer relative to the total weight of the composition.

2. Cosmetic or dermatological composition for topical application according to claim 1, characterized in that it comprises 0.01 to 0.15%, in particular 0.05 to 0.10% by weight of natural polysaccharide relative to the total weight of the composition.

3. Cosmetic or dermatological composition for topical application according to one of claims 1 and 2, characterized in that it comprises 0.10 to 0.25%, in particular 0.12 to 0.20% by weight of hydrobophobically modified crosslinked acrylic or methacrylic copolymer relative to the total weight of the composition.

4. Cosmetic or dermatological composition for topical application according to any of claims 1 to 3, characterized in that it further comprises an oat seedling extract.

5. Cosmetic or dermatological composition for topical application according to any of claims 1 to 4, characterized in that it is formulated in spray form.

6. Cosmetic or dermatological composition for topical application according to claim 5, characterized in that the spray works without propellants.

7. Cosmetic or dermatological composition for topical application according to any of claims 1 to 6, for its soothing, calming and / or anti-irritant use.

8. Dermatological composition according to any of claims 1 to 6, for use in the treatment of neurogenic skin inflammation by topical application.

9. Dermatological composition according to any of claims 1 to 6, for use in the treatment of inflammatory dermatoses selected from atopic dermatitis, eczema and psoriasis, by topical application.

10. Dermatological composition according to any of claims 1 to 6, for use in the treatment of itching and / or skin pain by topical application.

11. Dermatological composition for use according to claim 10, characterized in that the itching and / or skin pain is caused by a sting, a blow or a medical or surgical procedure, for topical application.